MX2021005877A - Compuesto heterociclico. - Google Patents
Compuesto heterociclico.Info
- Publication number
- MX2021005877A MX2021005877A MX2021005877A MX2021005877A MX2021005877A MX 2021005877 A MX2021005877 A MX 2021005877A MX 2021005877 A MX2021005877 A MX 2021005877A MX 2021005877 A MX2021005877 A MX 2021005877A MX 2021005877 A MX2021005877 A MX 2021005877A
- Authority
- MX
- Mexico
- Prior art keywords
- heterocyclic compound
- compound
- cocrystal
- solvate
- prophylactic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018222530 | 2018-11-28 | ||
| PCT/JP2019/046261 WO2020111087A1 (ja) | 2018-11-28 | 2019-11-27 | 複素環化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021005877A true MX2021005877A (es) | 2021-07-16 |
Family
ID=70853784
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021005877A MX2021005877A (es) | 2018-11-28 | 2019-11-27 | Compuesto heterociclico. |
| MX2024003064A MX2024003064A (es) | 2018-11-28 | 2021-05-19 | Compuesto heterociclico. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003064A MX2024003064A (es) | 2018-11-28 | 2021-05-19 | Compuesto heterociclico. |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US12152027B2 (enExample) |
| EP (1) | EP3888652A4 (enExample) |
| JP (2) | JP6972384B2 (enExample) |
| KR (2) | KR102646470B1 (enExample) |
| CN (2) | CN113038948B (enExample) |
| AU (1) | AU2019390863B2 (enExample) |
| BR (1) | BR112021009994A2 (enExample) |
| CA (1) | CA3120774A1 (enExample) |
| IL (2) | IL283368B2 (enExample) |
| MX (2) | MX2021005877A (enExample) |
| MY (1) | MY209902A (enExample) |
| PH (1) | PH12021551251A1 (enExample) |
| SG (1) | SG11202105652XA (enExample) |
| TW (3) | TWI784213B (enExample) |
| WO (1) | WO2020111087A1 (enExample) |
| ZA (1) | ZA202104402B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI784213B (zh) * | 2018-11-28 | 2022-11-21 | 日商武田藥品工業股份有限公司 | 雜環化合物 |
| EP4163280A4 (en) * | 2020-05-27 | 2024-06-05 | Takeda Pharmaceutical Company Limited | Method for producing heterocyclic compound |
| CN116916924A (zh) * | 2020-10-16 | 2023-10-20 | 稀有生物科学股份有限公司 | Malt1调节剂及其用途 |
| GB202018412D0 (en) | 2020-11-23 | 2021-01-06 | Exscientia Ltd | Malt-1 modulators ii |
| EP4291235A4 (en) * | 2021-02-12 | 2025-01-08 | Nimbus Saturn, Inc. | HPK1 ANTAGONISTS AND USES THEREOF |
| CN118451068A (zh) | 2021-12-30 | 2024-08-06 | 上海翰森生物医药科技有限公司 | 三并环类衍生物抑制剂、其制备方法和应用 |
| EP4473966A4 (en) * | 2022-02-02 | 2026-01-21 | Ono Pharmaceutical Co | CANCER TREATMENT AGENT COMPRISING A MALT1 INHIBITOR DRUG AS THE ACTIVE INGREDIENT |
| WO2025123039A1 (en) * | 2023-12-08 | 2025-06-12 | Shaman Pharma, LLC | Method for Production of Spiro-Oxindole and Indoxyl Derivatives of Mitragynine |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2288521A1 (fr) | 1974-10-25 | 1976-05-21 | Merck Patent Gmbh | Nouvelles penicillines et procede pour leur preparation |
| DE69633059T2 (de) * | 1995-05-31 | 2005-08-18 | Sumitomo Pharmaceuticals Co., Ltd. | Neue naphthyridinderivate. |
| GB9720052D0 (en) * | 1997-09-19 | 1997-11-19 | Smithkline Beecham Plc | Novel compounds |
| GB201321734D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| ES2738695T3 (es) | 2014-05-28 | 2020-01-24 | Novartis Ag | Nuevos Derivados de Pirazolo Pirimidina y su uso como inhibidores de MALT1 |
| US20200289514A1 (en) | 2015-11-13 | 2020-09-17 | Novartis Ag | Novel Pyrazolo Pyrimidine Derivatives |
| MX2019001132A (es) * | 2016-07-29 | 2019-12-16 | Lupin Ltd | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. |
| EP3535254A4 (en) | 2016-11-01 | 2020-06-24 | Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") | COMPOUNDS FOR THE DEGRADATION OF MALT1 |
| EP3592731A4 (en) | 2017-03-08 | 2020-10-07 | Cornell University | MALT1 INHIBITORS AND THEIR USES |
| US20200111087A1 (en) * | 2018-10-08 | 2020-04-09 | Jinlei Zhou | Method for encrypting digital contract document between contractors |
| TWI784213B (zh) * | 2018-11-28 | 2022-11-21 | 日商武田藥品工業股份有限公司 | 雜環化合物 |
-
2019
- 2019-11-27 TW TW108143201A patent/TWI784213B/zh active
- 2019-11-27 IL IL283368A patent/IL283368B2/en unknown
- 2019-11-27 SG SG11202105652XA patent/SG11202105652XA/en unknown
- 2019-11-27 TW TW113120662A patent/TW202438498A/zh unknown
- 2019-11-27 WO PCT/JP2019/046261 patent/WO2020111087A1/ja not_active Ceased
- 2019-11-27 CN CN201980078144.XA patent/CN113038948B/zh active Active
- 2019-11-27 JP JP2020557754A patent/JP6972384B2/ja active Active
- 2019-11-27 KR KR1020227003334A patent/KR102646470B1/ko active Active
- 2019-11-27 CA CA3120774A patent/CA3120774A1/en active Pending
- 2019-11-27 CN CN202410510968.2A patent/CN118420620A/zh active Pending
- 2019-11-27 KR KR1020217019537A patent/KR102359143B1/ko active Active
- 2019-11-27 US US17/296,434 patent/US12152027B2/en active Active
- 2019-11-27 EP EP19890558.0A patent/EP3888652A4/en active Pending
- 2019-11-27 AU AU2019390863A patent/AU2019390863B2/en active Active
- 2019-11-27 MY MYPI2021002948A patent/MY209902A/en unknown
- 2019-11-27 MX MX2021005877A patent/MX2021005877A/es unknown
- 2019-11-27 BR BR112021009994-8A patent/BR112021009994A2/pt unknown
- 2019-11-27 TW TW111139300A patent/TWI848400B/zh active
-
2021
- 2021-05-19 MX MX2024003064A patent/MX2024003064A/es unknown
- 2021-05-28 PH PH12021551251A patent/PH12021551251A1/en unknown
- 2021-06-25 ZA ZA2021/04402A patent/ZA202104402B/en unknown
- 2021-07-02 US US17/367,171 patent/US11230545B2/en active Active
- 2021-11-02 JP JP2021179627A patent/JP7434249B2/ja active Active
- 2021-11-17 US US17/528,677 patent/US11897879B2/en active Active
-
2023
- 2023-06-22 IL IL303962A patent/IL303962B1/en unknown
-
2024
- 2024-10-07 US US18/908,457 patent/US20250034141A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021005877A (es) | Compuesto heterociclico. | |
| CO2020006523A2 (es) | Compuestos moduladores de sting y métodos de elaboración y uso | |
| ECSP19030134A (es) | Compuesto de piridina | |
| SG11201901061QA (en) | Heterocyclic compound | |
| MX373786B (es) | Derivados de pirimidin-2,4-diamina para el tratamiento de cáncer. | |
| CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
| MX375970B (es) | Compuestos de triazolopirimidina y usos de los mismos. | |
| CO2017012067A2 (es) | Derivado de pirido[3,4–d]pirimidina y sal farmacéuticamente aceptable de éste | |
| EA201792116A1 (ru) | Ингибитор янус-киназы | |
| UY35683A (es) | Polimorfo de inhibidores de tirosina quinasa de bazo (syk) | |
| EA201690020A1 (ru) | Применение производных пиразолопиридина для лечения рака мочевого пузыря | |
| MX381970B (es) | Derivado de sulfonamida y composición farmacéutica que contiene el mismo. | |
| CO2019012125A2 (es) | Inhibidores ip6k | |
| CO2017003699A2 (es) | Compuesto heterocíclico | |
| MX2016009794A (es) | Derivado de sulfonamida heterociclico y medicina que comprende el mismo. | |
| MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| MX2017000208A (es) | Derivados de quinolizinona como inhibidores de pi3k. | |
| BR112019004236A2 (pt) | compostos para tratar doenças associadas a uma disfunção mitocondrial | |
| EA201692270A1 (ru) | Производные нафтиридиндиона | |
| MX2018009458A (es) | Derivado de sulfonamida heterociclico y medicina que contiene el mismo. | |
| SV2016005310A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
| CL2019002025A1 (es) | Derivados de pirrolotriazina como inhibidor de cinasas. | |
| MX2021000611A (es) | Una sal de xinafoato de un compuesto inhibidor de jak. | |
| ECSP12011747A (es) | Derivado de anillo heterocíclico fusionado y uso del mismo | |
| MY199524A (en) | Anti-angiogenic agents and uses thereof |